PTPRD and Ewing sarcoma: Shukla et al. [17] found BRAF, NRAS and CTNNB1 mutations in their ES patients and cell lines, while we found KRAS, PTPRD,GRB10 and MET. Together, these results suggest that advanced and resistant ES (and DSRCT) may be driven by diverse secondary aberrations.